Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823223 | 0.91 | NR1I2 (0.47) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL4826803 | 0.88 | PRKCA (0.51) | NR1I2PRKCAMMP12SCN9AOGFRL1 | |
| SCHEMBL13940285 | 0.88 | NR1I2 (0.42) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL3093361 | 0.86 | PRKCA (0.52) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL772587 | 0.85 | SCN9A (0.47) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL771196 | 0.85 | SCN9A (0.49) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL12429623 | 0.84 | SCN9A (0.43) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL3565283 | 0.83 | PRKCA (0.46) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL4822935 | 0.82 | PRKCA (0.39) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL13941052 | 0.82 | PRKCA (0.46) | NR1I2PRKCAMMP12SCN9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558252-B1 | SUBSTITUTED FURO [2,3-B]PYRIDINE DERIVATIVES | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | claimed |
| EP-2121707-B1 | ANTIVIRAL INDOLES | ANGELETTI P IST RICHERCHE BIO (IT) | 2012-12-05 | — | — | EP | disclosed |
| US-8101595-B2 | Antiviral indoles | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA (IT) | 2012-01-24 | — | — | US | disclosed |
| US-20100076046-A1 | Antiviral Indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-03-25 | — | — | US | disclosed |
| US-7662809-B2 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-02-16 | — | — | US | disclosed |
| US-20080261938-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-23 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1807397-A2 | TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2007-07-18 | — | — | EP | disclosed |
| EP-1776368-A1 | INHIBITORS OF HCV REPLICATION | Bristol-Myers Squibb Company (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| WO-2006046039-A2 | TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2006-05-04 | — | — | WO | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
| WO-2006020082-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076046-A1 | Antiviral Indoles | IDO1, ZC3HAV1, IFNAR1 | NR1I2 674/4885PRKCA 4625/4885MMP12 2333/4885 |
| US-20080261938-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, HAVCR2 | NR1I2 164/4885PRKCA 4232/4885MMP12 2495/4885 |
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | NR1I2 1013/4885PRKCA 3479/4885MMP12 3512/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | NR1I2 1013/4885PRKCA 3479/4885MMP12 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.